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Abstract
Transforming growth factor-beta (TGF-b), a multifunctional cytokine regulating several immunologic processes, is expressed
by virtually all cells as a biologically inactive molecule termed latent TGF-b (LTGF-b). We have previously shown that TGF-b
activity increases during influenza virus infection in mice and suggested that the neuraminidase (NA) protein mediates this
activation. In the current study, we determined the mechanism of activation of LTGF-b by NA from the influenza virus A/
Gray Teal/Australia/2/1979 by mobility shift and enzyme inhibition assays. We also investigated whether exogenous TGF-b
administered via a replication-deficient adenovirus vector provides protection from H5N1 influenza pathogenesis and
whether depletion of TGF-b during virus infection increases morbidity in mice. We found that both the influenza and
bacterial NA activate LTGF-b by removing sialic acid motifs from LTGF-b, each NA being specific for the sialic acid linkages
cleaved. Further, NA likely activates LTGF-b primarily via its enzymatic activity, but proteases might also play a role in this
process. Several influenza A virus subtypes (H1N1, H1N2, H3N2, H5N9, H6N1, and H7N3) except the highly pathogenic H5N1
strains activated LTGF-b in vitro and in vivo. Addition of exogenous TGF-b to H5N1 influenza virus–infected mice delayed
mortality and reduced viral titers whereas neutralization of TGF-b during H5N1 and pandemic 2009 H1N1 infection
increased morbidity. Together, these data show that microbe-associated NAs can directly activate LTGF-b and that TGF-b
plays a pivotal role protecting the host from influenza pathogenesis.
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Introduction
Transforming growth factor-b1 (TGF-b) is the prototypic
member of a family of multifunctional cytokines that modulate
diverse cellular, developmental, and immunological processes
(reviewed in [1–3]). TGF-b is secreted by virtually all cells as a
biologically inactive moleculetermed latent TGF-b (LTGF-b) [4,5].
The latent complex consists of an N-terminal latency-associated
peptide (LAP) and the mature TGF-b domain. LAP and TGF-b are
productsofasinglegene,whichafterposttranslationalmodifications
such as glycosylation and phosphorylation and cleavage by furin
remain noncovalently associated, forming the small latent complex
[6]. The small latent complex is secreted by cells as an inactive
complex, and insome cases is linkedby a disulfidebond tothelatent
TGF-b-binding protein to form the large latent complex.
The non-covalent association of LAP with the mature domain is
critical for latency. The molecular mechanism by which LAP
confers latency to mature TGF-b is largely unknown. However,
recent studies suggest that amino acids 50–85, several of which are
glycosylated and contain terminal sialic acid residues, are critical
for proper formation and function of the LTGF-b complex [7].
Mutations in this region reduce the binding of LAP to the mature
domain and significantly impair the ability of LAP to confer
latency to mature TGF-b [8]. Agents that activate the latent
complex can disrupt the association of LAP with the mature
domain either by proteolysis or denaturing the LAP or by altering
its folding [6]. Given the abundance of LTGF-b and the
prevalence of high-affinity receptors on most cell types, the
activation of LTGF-b is recognized as a crucial step in TGF-b
function (reviewed in [9,10]).
PLoS Pathogens | www.plospathogens.org 1 October 2010 | Volume 6 | Issue 10 | e1001136Chaotropic agents, heat, reactive oxygen species [11,12], and
extreme pH [13,14] can activate LTGF-b. In vitro studies have
identified proteases, which degrade the LAP (reviewed in [15]),
and molecules such as thrombospondin-1, which alter the
conformation of the LAP [16,17,18,19,20], as putative physiolog-
ical TGF-b activators. Less is known about activation in vivo,
although integrins appear to be the primary LTGF-b activators in
the lung [10,21,22].
Little is known about the direct activation of LTGF-b by
microbes. Several parasites such as Trypanosoma cruzi, Leishmania
spp., and Plasmodium spp. and the bacteria Mycobacterium tuberculosis
activate LTGF-b through proteolysis, using either host-derived
plasmin or microbe-encoded proteases [23–26]. In a previous
study, we have shown that influenza viruses activate TGF-b in vitro
and in vivo [27]. Antibodies to the viral neuraminidase (NA) protein
inhibited viral-induced LTGF-b activation, suggesting that NA
plays a role in LTGF-b activation, but the precise mechanism of
activation remains to be identified and the role of TGF-b in
influenza disease is unknown. In this study, we determined the
mechanism of activation of rLTGF-b by viral and bacterial NA.
Since NA is essential for viral replication, we tested a panel of
influenza virus subtypes (including two 2009 H1N1 pandemic
strains) for their ability to activate LTGF-b in vitro. For strains that
failed to activate LTGF-b, we used reverse genetic studies to
determine whether these viruses had deficient NA activity. We also
investigated whether exogenous TGF-b provides protection from
H5N1 influenza pathogenesis and whether depletion of TGF-b
during virus infection increases morbidity in mice.
Results
Purified NA activates LTGF-b
To begin defining the mechanism of NA-mediated activation of
LTGF-b, we first asked if NA purified from the virion was
sufficient for activation. Thus, recombinant LTGF-b (rLTGF-b)
was incubated with buffer alone, purified A/Gray Teal/Australia/
2/1979 virus (N4 virus), purified Gray Teal NA (N4 NA, BEI
Resources, Manassas, VA), or low-protease-content NA purified
from Clostridium perfringens (Roche), which was used as a non-viral
NA control (bNA). All the samples were standardized to equivalent
NA enzymatic activity and rLTGF-b activation was monitored by
two different assays; the PAI/L bioassay, which monitors the
activation of a TGF-b-specific reporter construct expressed in a
stable cell line, or a sandwich ELISA specifically recognizing an
epitope on the active TGF-b protein. All of the samples activated
rLTGF-b in both assays in a dose-dependent manner. In the PAI/
L bioassay, the concentration of active TGF-b increased with
increasing amounts of NA (Fig. 1A). However, at the highest
concentration of N4 virus (180,000 RFU) there was no TGF-b
activity and the cells appeared dead. In the ELISA, both the N4
virus and purified NAs had low, but detectable levels of TGF-b
activity at the lowest dose tested (10,000 RFU), that increased at
30,000 RFU, and then remained steady at the higher NA
concentrations (Fig. 1B). Overall, these studies demonstrate that
both influenza viral and a bacterial NA can activate LTGF-b.
NA removes sialic acids on the LAP
To determine if NA-mediated activation involved removal of the
sialic acid motifs on the LAP, rLTGF-b was incubated with PBS,
bNA, N4 virus, or purified N4 NA, and the size of the LAP was
determined by Western blot. HCl was used as a control for non-
enzymatic-mediated activation of rLTGF-b. The rLTGF-b incu-
bated with bNA, N4 virus, and N4 NA showed a slight shift in
mobilityofthe LAPascompared tothat incubatedwithPBSorHCl
(Fig. 2A). There was no significant difference in the mobility
between the bNA, N4 virus, and N4 NA. This shift in mobility was
not evident when N4 NA was incubated with rLTGF-b purified
from insect cells (Fig. 2B). The rLTGF-b produced by insect cells is
unsialylated, as insect cells have no detectable sialyltransferase
activity [28]. Thus, the lack of size change upon incubation with N4
NA suggests that the increased mobility of LTGF-b treated with N4
virus, bNA, or N4 NA is due to removal of sialic acid moieties. To
confirm this, rLTGF-b was incubated with PBS, bNA, or N4 NA,
proteins separated on a reducing SDS-PAGE, and sialic acid
expression monitored by Western blot analysis using digoxigenin
(DIG)–labeled lectins Maackia amurensis agglutinin (MAA; recognizes
a2-3 sialic acid linkages, Fig. 2C) or Sambucus nigra agglutinin (SNA;
Figure 1. NA activates LTGF-b. rLTGF-b (10 ng/ml) was incubated
a l o n e( w h i t eb a r )o rw i t hi n c r e a s ing amounts of enzymatically
equivalent amounts of bacterial NA (bNA, black bar), N4 virus (red
bar), or purified Gray Teal NA (gray bar) for 1 h at 37uC and TGF-b
activity (pg/ml) measured by the PAI/L assay (A) or ELISA (B). Error bars
represent standard error of the mean.
doi:10.1371/journal.ppat.1001136.g001
Author Summary
Transforming growth factor-beta (TGF-b) is a multifunc-
tional protein that serves as a global regulator of immunity
by controlling the initiation and resolution of inflammatory
responses. A pathogen that can regulate TGF-b activation
could promote an immune-privileged state for itself within
its host. Indeed, multiple parasitic, bacterial, and fungal
pathogens successfully evade immune responses by
regulating TGF-b. We demonstrate that the neuraminidase
proteins from influenza A viruses and Clostridium perfrin-
gens convert biologically inactive TGF-b to its active form.
Importantly, modulation of TGF-b activity during influenza
infection affects viral titers and disease outcome in mice,
suggesting that TGF-b plays an important role in influenza
pathogenesis, particularly in protecting the host during
infection. These studies suggest that neuraminidases from
diverse microbes may be able to directly regulate TGF-b,
which may in turn play an important role in disease.
Neuraminidase Activates TGF-b
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with anti-LAP to confirm that the protein analyzed was the LAP
(Fig. 2D). rLTGF-b incubated with PBS was detected by both SNA
and MAA, suggesting the presence of both a2-6 and a2-3–linked
sialic acids on the LAP (Fig. 2C and Fig. S1). In contrast, MAA and
SNA failed to recognize bNA-treated rLTGF-b. Similarly, N4 NA–
treated rLTGF-b was not recognized by MAA (Fig. 2C), but was
detected by SNA (Fig. S1). However, this doesnot imply that the N4
NA fails to cleave a2-6 linkages. Hence, the mobility shift observed
when rLTGF-b was incubated with NA is likely because of the loss
of LAP-associated a2,3-linked sialic acids, but the specific sialic acid
linkages removed may depend on the NA, as seen in the case of
bNA-treated rLTGF-b.
NA enzymatic activity is involved in rLTGF-b activation,
but proteases may also play a role in this process
To determine whether the enzymatic activity of NA was
required for loss of specific sialic acid motifs and TGF-b activation,
N4 virus or NA was pre-incubated with the influenza-specific
inhibitor (NAi) oseltamivir carboxylate (10 nM) before incubation
with rLTGF-b. Pre-incubation with NAi inhibited the mobility
shift in the LAP (Fig. 2A), the loss of sialic acid (Fig. 2C), and TGF-
b activation (Fig. 3A and B). N4 virus and NA–induced activation
was completely inhibited with 10 nM NAi in the PAI/L assay
(Fig. 3A) and to a lesser degree (75–95%) in the ELISA (Fig. 3B).
Increasing the concentration of NAi up to 10 mM failed to
completely inhibit activation in the ELISA assay (data not shown).
Because the NAi is specific for influenza NA, it did not inhibit
bNA-induced activation of rLTGF-b (Fig. 3A and 3B).
Proteases are established activators of LTGF-b [15] and can be
contaminants of viral preparations or even components of the viral
Figure 2. NA induces a shift in the size of LAP and removes
sialic acids from the LAP. rLTGF-b (0.4 mg) was incubated with PBS,
HCl (pH 2), bacterial NA (bNA), purified Gray Teal virus (GT Virus, 2 mg),
or purified Gray Teal NA (GT NA, 0.5 mg) in the presence or absence of
1 mM oseltamivir carboxylate (NAi) or 16protease inhibitor cocktail (PI)
for 1 h at 37uC. Proteins were separated by SDS-PAGE under reducing
conditions, transferred to nitrocellulose, and probed with anti-LAP
antibody (A and D) or DIG-labeled MAA lectin (C) by Western blot
analysis. (B) Insect cell–derived rLAP (0.5 mg) was incubated as
described above and probed with anti-LAP antibody by Western blot
analysis. bNA and GT NA alone were run as controls for (C).
doi:10.1371/journal.ppat.1001136.g002
Figure 3. Role for NA activity and proteases in LTGF-b
activation by influenza virus. (A) rLTGF-b (10 ng/ml) was incubated
alone (black bar) or with bNA (30,000 RFU NA activity), purified N4 virus
(90,000 RFU NA activity), or purified N4 NA (90,000 RFU NA activity) in
the presence or absence of 16 PI cocktail (red bars) or 10 nM
oseltamivir carboxylate (NAi, gray bars) for 1 h at 37uC. TGF-b levels
were measured by (A) PAI/L assay or (B) ELISA. (C) rLTGF-b (10 ng/ml)
was incubated with purified Tk/WI virus (10
6 TCID50 units/ml) alone or in
the presence of increasing concentrations of bestatin (&, nM),
leupeptin (N, mM) or GM1489 (D, nM), and TGF-b activity measured by
ELISA. Error bars represent standard error of the mean. Asterisk (*)
indicates significant inhibition as compared with virus/NA-treated LTGF-
b in the absence of inhibitor.
doi:10.1371/journal.ppat.1001136.g003
Neuraminidase Activates TGF-b
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shift and activation assays were performed in the presence of a
broad-spectrum protease inhibitor (PI) cocktail. The PI cocktail
used in these studies had no effect on sialidase activity of either the
virus or NAs and did not inhibit active TGF-b detection in either
assay (data not shown). Unlike NAi, pre-incubation with PI had no
effect on the LAP mobility shift (Fig. 2A). However, the PI
inhibited the N4 virus and NA-induced activation of LTGF-b in
the ELISA assay (Fig. 3B) and to some extent in the PAI/L assay
(Fig. 3A), although the inhibition was not as much as that seen
with NAi treatment. To determine the specific class of proteases
causing the inhibition, virus was pretreated with increasing
concentrations of individual protease inhibitors within their
effective inhibitory ranges and incubated with rLTGF-b, and
TGF-b activity was determined by ELISA (Fig. 3C). None of the
protease inhibitors blocked rLTGF-b activation by the N4 virus.
Further, when incubated with substrate for 1 h, all reagents tested
protease-free (negative for trypsin, chymotrypsin, thrombin,
plasmin, elastase, subtilisin, papain, cathepsin B, thermolysin,
and pepsin) in a fluorescein thiocarbamoyl-casein derivative-based
assay kit (data not shown). Even when incubations were extended
to 24 h, only few viral stocks were positive for proteases (Fig. S2).
Together, these data suggest that NA activates LTGF-b primarily
via a mechanism involving enzymatic activity. However, a role for
proteases cannot be discounted especially during infection in vivo.
Most influenza strains activate LTGF-b
As NA is essential for viral replication, we hypothesized that all
influenza strains could activate LTGF-b. rLTGF-b was incubated
with a panel of influenza virus subtypes, including two 2009 H1N1
pandemic strains, and several highly pathogenic avian influenza
viruses (H5N1 and H5N9), and TGF-b activity was measured by
the PAI/L assay (Fig. 4A) or ELISA (Fig. 4B). Although most of
the strains activated LTGF-b, the levels of activation differed
despite having equivalent NA activity. Surprisingly, several of the
H5N1 influenza viruses failed to activate rLTGF-b; only A/Hong
Kong/486/1997 (HK/486) consistently activated rLTGF-b
(Fig. 4A and 4B). Incubation of rLTGF-b with a representative
non-activating H5N1 virus, A/Hong Kong/483/1997 (HK/483),
did not cause the expected mobility shift in the LAP (Fig. 4C),
suggesting that the NA from viruses that did not activate rLTGF-b
may also not cleave sialic acids from the LAP.
There is no intrinsic defect in the H5N1 viral NA
To determine whether the failure of H5N1 viruses to activate
rLTGF-b was due to an intrinsic defect in the H5 NA protein, we
first examined rLTGF-b activation by A/Teal/Hong Kong/
W312/97 (Teal/HK) H6N1 virus. Teal/HK NA shares 97%
sequence nucleotide homology with the H5N1 NA including a 19-
amino-acid deletion in the stalk region and is the proposed donor
of the NA and the internal genes of the H5N1 viruses [31]. Unlike
the H5N1 viruses, Teal/HK virus activated rLTGF-b in both
assays (Fig. 4A and 4B) suggesting that the deletion in the NA stalk
domain has no effect on TGF-b activation.
To further assess the H5N1 NA, two H1N1 influenza viruses
(A/California/04/09 and A/Puerto Rico/8/34) expressing the
HK/483 NA were generated (CA/09+HK/483 NA and
PR8+HK/483 NA) and tested for rLTGF-b activation. Both the
parental viruses and the reassortant viruses containing the HK/
483 NA activated rLTGF-b in the PAI/L (Fig. 5A) and ELISA
(Fig. 5B) assays. Further, activation was inhibited by NAi but not
the PI cocktail (Fig. 5C), confirming that the HK/483 NA can
activate rLTGF-b in a NA-dependent manner.
H5N1 viral NA fails to activate rLTGF-b on an H5 virus in
vitro and in vivo
To construct an H5N1 virus that activated rLTGF-b, HK/483
virus expressing the HK/486 NA was generated. Unfortunately,
this virus was unable to activate rLTGF-b (Fig. 5A and 5B).
Further, expressing the HK/483 NA on the HK/486 virus led to
reduced activation as compared to the parental HK/486 virus. To
evaluate LTGF-b activation in vivo, BALB/c mice were intrana-
sally inoculated with PBS (control, n=8)or10
4 TCID50 units of
the different reassortant viruses (n=10) and lungs collected at 2, 4,
and 7 days post-infection (dpi). Active or total (determined by acid
activation of the sample) levels of TGF-b in the lung homogenates
were determined by ELISA (Fig. 5D). Similar to the in vitro results,
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Figure 4. Influenza viruses differentially activate LTGF-b. rLTGF-
b (10 ng/ml) was incubated alone (white bar) or with different influenza
virus subtypes (90,000 RFU) for 1 h at 37uC and TGF-b activity measured
by PAI/L assay (A) or ELISA (B). (C) rLTGF-b (0.4 mg) was incubated with
PBS, bNA, N4 Virus (2 mg), or HK/483 virus (HK/483, 2 mg) in the
presence or absence of 1 mM oseltamivir carboxylate (NAi) for 1 h at
37uC. Proteins were separated by SDS-PAGE under reducing conditions,
transferred to nitrocellulose, and probed with anti-LAP antibody by
Western blot analysis. Error bars represent standard error of the mean.
doi:10.1371/journal.ppat.1001136.g004
Neuraminidase Activates TGF-b
PLoS Pathogens | www.plospathogens.org 4 October 2010 | Volume 6 | Issue 10 | e1001136Figure 5. Reassortant viruses differentially activate rLTGF-b. rLTGF-b (10 ng/ml) was incubated alone (white bar), or with equivalent levels
(90,000 RFU NA activity) of parental CA/09 (red bars), parental PR8 (dark gray bars) or parental HK/486 (light gray) viruses, or reassortant viruses
expressing the HK/483 NA (hatched bars) for 1 h at 37uC and TGF-b activity measured by PAI/L assay (A) or ELISA (B). (C) rLTGF-b (10 ng/ml) was
incubated with bNA, parental PR8 virus, or the PR8+HK/483 NA viruses alone (black bars) or in the presence or absence of 16PI cocktail (red bars) or
10 nM oseltamivir carboxylate (gray bars) for 1 h at 37uC and TGF-b activity measured by ELISA. (D) BALB/c mice (4–6 weeks old) were inoculated i.n.
with PBS (control, n=8), or 10
4 TCID50 units of the parental or reassortant viruses (n=10) and lungs collected at 2, 4, and 7 dpi. Total (acid-activated
samples) and active TGF-b levels were monitored in the lung homogenates by the mouse TGF-b–specific ELISA. Error bars represent standard error of
the mean.
doi:10.1371/journal.ppat.1001136.g005
Neuraminidase Activates TGF-b
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mice as compared to PBS-inoculated mice. Levels of active TGF-b
were increased .5-fold within 2 dpi, remained elevated at 4 dpi,
before returning to control levels at 7 dpi (Fig. 5D). These kinetics
were similar to those observed in mice infected with PR8 virus [27]
and other highly pathogenic avian influenza viruses [32].
The total TGF-b levels in the lungs remained constant for all
the viruses except for a significant decrease (,60%) in the HK/
483 infected mice at 2 dpi (Fig. 5D). This decline was not seen in
mice infected with the HK/483+HK/486 NA reassortant virus,
which remained at control levels at 2 dpi. These findings suggest
that the NA may influence the total levels of TGF-b in the lungs of
infected mice through an undefined mechanism.
Exogenous TGF-b provides partial protection during
HK/483 infection
Because we were unable to construct an HK/483 H5N1 virus
that activates TGF-b in vivo, active TGF-b1 was administered to
HK/483-infected mice by using a replication-deficient adenovirus
vector. Twenty-four hours after HK/483 infection (10
4 TCID50),
10
8 PFUs of control adenovirus vector (AdDL70, n=12), TGF-b-
expressing vector AdTGFb
223/225 (n=12), or PBS (n=12) were
administered intranasally. Lung TGF-b levels were measured at 2,
4, and 7 dpi. By 2 dpi, TGF-b levels in the lung increased to
approximately 450 pg/ml in mice treated with the TGF-b–
expressing adenovirus and remained above control levels even at
7 dpi (Fig. 6A). Mice treated with the control virus AdDL70
showed a transient increase in lung TGF-b activity at 2 dpi
(100 pg/ml), which returned to control levels by 4 dpi. By 4 dpi
with the HK/483 virus, all infected mice lost approximately 15%
(p,0.01) of their initial body weight, which increased to more than
20% by 7 dpi in the HK/483 and +AdDL70 groups (Fig. 6B), at
which time mice either succumbed to infection or were euthanized
(Fig. 6C). Mice inoculated with AdTGFb
223/225 showed delayed
weight loss and prolonged survival. At 7 dpi, weight loss remained
at approximately 15% (p,0.01), but increased to 25% by 9 dpi
(Fig. 6B). This was associated with a significant delay in mortality:
AdTGFb
223/225- infected mice survived until 10 dpi (p,0.05,
Fig. 6C). These mice also had significantly lower viral titers than
HK/483-infected mice (Fig. 6D). By 2 dpi (1 day post
AdTGFb
223/225 inoculation), viral titers decreased from approx-
imately 10
7.5 TCID50 to 10
5.5 TCID50 (p,0.05) in the HK/483
alone and AdDL70 groups. Similar decreases in titers were
observed at 4 and 7 dpi (p,0.05) in the HK/483 alone group.
However, there was no significant difference in titers between the
AdDL70 and AdTGFb
223/225 groups at 4 dpi.
GiventheincreasedsurvivalofmiceinfectedwithAdTGFb
223/225,
we tested whether pretreatment with TGF-b afforded additional
protection to mice. Mice (n=12) were administered 10
8 PFUs
AdDL70 control or the AdTGFb
223/225 virus 48 h before HK/483
infection. Pretreatment with AdTGFb
223/225 provided no added
protection; all the HK/483-infected mice succumbed to infection by
8 dpi (Fig. S3B). Both the uninfected and HK/483-infected mice
pretreated with AdTGFb
223/225 lost significantly more weight by
4 dpi than mice in other groups (10% vs. 0%, p,0.01, Fig. S3A),
suggesting that increased TGF-b activity before H5N1 influenza
infection can be detrimental to mice.
Depletion of TGF-b during HK/486 or pandemic 2009
H1N1 infection increases morbidity
We then examined the effect of removing TGF-b during
HK/486 infection by depleting TGF-b using a pan-TGF-b
neutralizing antibody. Briefly, 1D11 antibody or isotype-
control IgG was administered and total TGF-b levels in the
lungs were monitored by ELISA (Fig. 7A). Total TGF-b levels
in HK/486-infected mice were significantly (3 times) lower
(p=0.0003) by 24 hpi than in the HK/486-infected mice
receiving isotype IgG. Two doses of the neutralizing antibody
decreased TGF-b levels to control levels; by 7 dpi, levels were
Figure 6. Exogenous TGF-b delays mortality in HK/483-infected
mice. BALB/c mice (4–6 weeks old) were inoculated i.n. with PBS
(control, n=10), or 10
4 TCID50 units of HK/483 virus and 24 hpi
inoculated with 10
8 PFU/mouse of a TGF-b-expressing adenovirus
(AdTGFb
223/225) or a control adenovirus vector (AdDL70) (infected
groups, n=12). Mice inoculated with AdDL70 or AdTGFb
223/225 alone
served as controls (n=10). At 2, 4, and 7 days post HK/483 infection (1,
3, and 6 day post-adenovirus administration), lung homogenates were
monitored for TGF-b levels by a mouse-specific ELISA (A) and viral titers
by TCID50 analysis on MDCK cells (D). For titers, red bars, day 2pi; dark
gray bars, day 4 pi; and gray bars, day 7 pi. Weights (B) and survival (C)
were monitored for 10 dpi. Error bars represent standard error of the
mean. Asterisk (*) indicates significant increase in TGF-b levels as
compared with other groups (A); difference in weight loss (B) or
mortality (C) as compared with HK/483 virus and AdDL70-treated mice;
and decrease in viral titers as compared with HK/483 infected mice (D).
doi:10.1371/journal.ppat.1001136.g006
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8 dpi, all HK/486-infected mice (10
5 TCID50, n=15) lost
approximately 20% of their starting weight whereas HK/486-
alone mice lost only 10% (Fig. 7B, p,0.01). By 9 dpi, 40% of
mice in the TGF-b–depleted group succumbed to infection, and
all died by 10 dpi (Fig. 7C), whereas those in the HK/486 and
isotype IgG groups began to recover and gain weight. The
increased mortality in the TGF-b–depleted group was not
associated with a significant increase in viral replication. HK/
486-infected mice with and without isotype IgG had peak lung
titers of approximately 10
4.6 TCID50 by 2 dpi, which decreased
to 10
1.5 TCID50 by 10 dpi (Fig. 7D). In contrast, the TGF-b–
depleted group had a slight, although not significant, increase in
viral titers at 2 and 4 dpi. At 8 dpi, 1D11-treated mice had a 15-
fold increase in viral titers over HK/486 and isotype IgG–
treated mice (p,0.02). No virus was detected in control tissues
or outside the lungs of infected mice.
To determine if these findings were specific to the highly
pathogenic H5N1 influenza viruses, mice (n=6) were pre-treated
with PBS, the 1D11 antibody or isotype-control IgG as described,
infected with A/California/04/09 (CA/09, 10
5 TCID50), and
monitored for morbidity. The CA/09-infected mice treated with
PBS or receiving the isotype IgG lost approximately 20–25% of
their starting weight by 6 to 8 dpi before returning to day 0
weights by 12 dpi (Fig. 8A). Clinically the mice had ruffled fur and
were shivering. The 1D11-treated mice followed a similar pattern
but lost significantly more weight by 6 dpi (p=0.047) and had a
delayed recovery with significantly more weight loss still evident at
12 dpi (p=0.029). The 1D11-treated mice had more significant
clinical signs of infection including rear-leg paralysis and had 20%
mortality by 8 dpi reaching 67% by 12 dpi (Fig. 8B). Taken
together, the data suggest that TGF-b is modulated by the virus,
and this modulation during infection may be important in disease
outcome.
Figure 7. Depletion of TGF-b alters morbidity in HK/486-
infected mice. Six hours before infection, BALB/c mice were treated
with a TGF-b neutralizing antibody (1D11) or an isotype control
antibody (IgG) at a dose of 0.5 mg/mouse and subsequently inoculated
with PBS (control) or 10
5 TCID50 units of HK/486 virus (n=15).
Antibodies were readministered every 48 hpi. At 0, 1, 4, and 7 days
pi, total TGF-b levels were analyzed in lung homogenates by a mouse
TGF-b-specific ELISA (A). Weights (B) and survival (C) were monitored for
14 dpi. On days 2, 4, 8, and 10 pi, lung homogenates were monitored
viral titers by TCID50 analysis on MDCK cells (D). Error bars represent
standard error of the mean. Asterisk (*) indicates significant decrease in
TGF-b levels as compared with infected group treated with IgG (A), and
increase in viral titers as compared with HK/486-infected mice with and
without IgG treatment (D).
doi:10.1371/journal.ppat.1001136.g007
Figure 8. Depletion of TGF-b alters morbidity in HK/486-
infected mice. Forty-eight hours before infection, BALB/c mice were
treated with a TGF-b neutralizing antibody (1D11) or an isotype control
antibody (IgG) at a dose of 0.5 mg/mouse and subsequently inoculated
with PBS (control) or 10
5 TCID50 units of CA/09 virus (n=6). Antibodies
were re-administered every 48 hpi. Mice were monitored daily for
weight loss (A) and mortality (B). Error bars represent standard error of
the mean. Asterisk (*) indicates significant weight loss as compared to
HK/486 infected mice.
doi:10.1371/journal.ppat.1001136.g008
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These studies establish NA as a direct activator of LTGF-b and
demonstrate a role for TGF-b in protection against influenza virus
pathogenesis. We have previously shown that purified influenza
virus activates TGF-b [27] and that antibodies to the viral NA but
not the HA inhibit viral-mediated LTGF-b activation. In this
study, we demonstrate that purified NA alone can convert the
biologically latent form of TGF-b to its active form and that TGF-
b plays an important role in protection against influenza virus
pathogenesis. Activation of LTGF-b by viral NA involves removal
of sialic acid moieties to release the active TGF-b molecule from
the latent complex or expose other residues for cell surface
interactions. To our knowledge, these are the first studies
demonstrating that microbe-associated sialidases can directly
activate LTGF-b.
Our study also shows that NA-mediated LTGF-b activation is
not specific to influenza virus. As the topology of the NA catalytic
domain is well conserved and the active sites share many structural
features [33], NAs from diverse pathogens may activate LTGF-b.
In our study, Clostridium perfringens–derived bNA also activated
LTGF-b, which is consistent with previous studies showing LTGF-
b activation by bNA, although sialidase activity was not explicitly
identified as the means of activation [34,35]. Paramyxoviruses,
which also have a functional NA protein, directly activate LTGF-b
(unpublished data). A study by Zou and Sun demonstrated that
LTGF-b2 and LTGF-b3 were also activated by NA [36],
suggesting that NA may be a biological activator of numerous
types of LTGF-b.
Despite the functional conservation among NAs, some highly
pathogenic avian (HPAI) H5N1 influenza viruses failed to activate
LTGF-b in vitro and in vivo [32,37]. The NA from these viruses has
a 19-amino-acid deletion in the stalk [31,38] that could contribute
to the decreased ability to activate LTGF-b. To test this possibility,
we assessed the activation of rLTGF-b by the Teal/HK H6N1
virus. Hoffmann et al., proposed that this virus may have donated
the NA gene to the H5N1 viruses given the high degree of
nucleotide homology [31]. In spite of the stalk deletion, Teal/HK
activated rLTGF-b unlike the H5N1 viruses. Further, expressing
the HK/483 NA on either PR8 or CA/09 virus had no effect on
rLTGF-b activation suggesting that there is no intrinsic defect in
the NA.
However, expressing the HK/483 NA on the H5 HK/486 virus
led to an inability to activate LTGF-b in vitro and in vivo.I n
addition the HK/486 NA failed to rescue the activation phenotype
with the HK/483 virus. A recent study by Matsuoka et al
demonstrated that short-stalk NAs from the H5N1 viruses are
more virulent in mice and chickens. Intriguingly, the NA-mediated
virulence can be affected by HA glycosylation. Virulence in mice
conferred by a short stalk NA was most evident when the HA had
no glycosylation [38]. Although virulence in vivo is much more
complicated than LTGF-b activation, studies are underway to
examine the role of HA in LTGF-b. We hypothesize that although
HA will not be directly involved in activation, it may influence the
ability of NA to activate.
The question remains whether NA-mediated activation has an
important biological role in TGF-b activation during influenza
infection in vivo. At this time we can’t definitively answer that
question. What is intriguing is that the NA may influence the total
levels of lung TGF-b during infection. Mice infected with HK/483
had a dramatic decrease in total LTGF-b levels by 2 dpi (from
,2000 pg/ml to ,1000 pg/ml). This phenotype was reversed
with the HK/483 virus expressing the HK/486 NA. A similar
trend was seen when HK/483 NA was expressed on HK/486; a
significant decrease in total TGF-b levels. Studies are on-going to
determine if this is due to a change in the cells in the lung
associated with TGF-b secretion or if the viruses differentially
regulate the known physiologic activators.
There are numerous physiologic TGF-b activators in the lung:
the infected epithelium could release thrombospondin-1, proteases
and matrix metalloproteases, or even reactive oxygen species
(reviewed in [15,21,39]). Virus-induced injury to the epithelium
can directly activate LTGF-b through the induction of apoptosis
[40] or the upregulation of integrins [41–44], and immune cells
have high levels of active TGF-b [45,46]. Proteases may play a
role in influenza virus-induced LTGF-b activation, especially
during influenza infection in vivo, wherein cellular proteases are
essential for influenza virus replication (reviewed in [47–50]).
Proteases can be contaminants of viral preparations or even
components of the viral membrane [29,30]. Thus, only protease-
free reagents were used in our assays, and a broad-spectrum PI
cocktail partially blocked influenza virus and NA-mediated LTGF-
b activation. Further studies confirmed that the broad-spectrum PI
cocktail had no effect on either sialidase activity (as measured in
the MUNANA assay) or directly on TGF-b detection in either
assay (data not shown). However, we have not been able to identify
the specific class of proteases or a potential cleavage site within
LTGF-b by mass spectrometry (data not shown).
Since our initial attempts to construct H5 viruses that can
activate TGF-b in vivo were unsuccessful, we evaluated the role of
TGF-b in influenza pathogenesis by using a neutralizing
antibody and administering exogenous TGF-b via an adenovirus
vector. Mice administered TGF-b neutralizing antibody during
HK/486 H5N1 infection had higher morbidity and mortality
than mice treated with control virus or isotype IgG. This finding
was not specific to H5N1 influenza viruses; inhibiting TGF-b
activity during 2009 H1N1 infection also increased morbidity.
Although mice exhibited clinical signs of illness, administrationof
exogenous TGF-b to HK/483-infected mice once at 24 hpi
delayed morbidity and mortality. Administration of exogenous
TGF-b 48 h pre-infection did not affect survival, and TGF-b–
treated infected and non-infected mice had increased weight loss
by 4 dpi, suggesting that the timing of TGF-b activation may be
important.
Although we are still investigating the specific protective role
of TGF-b during influenza infection, we did find that mice
administered exogenous TGF-b had significantly lower titers
within 2 dpi than untreated infected and AdDL70-treated mice.
This decrease in viral load may contribute to the delayed
morbidity observed, but was not sufficient to protect mice from
severe infection. In contrast, depleting TGF-b during HK/486
infection had little to no significant effect on viral load until
8 dpi. Thus, mechanisms other than reduction of viral load may
be involved in TGF-b–mediated modulation of influenza
pathogenesis.
TGF-b serves as a global regulator of immunity by controlling
the initiation and resolution of inflammatory responses (reviewed
in [39,46]). Thus, a pathogen that can regulate TGF-b activation
could promote an immune-privileged state for itself within its host,
as has been seen in the case of multiple parasitic, bacterial, and
fungal pathogens (reviewed in [46,51–55]). We postulate that
failure of certain H5N1 influenza viruses to activate TGF-b
[56,57] may result in improper immune stimulation and
resolution, contributing to exacerbated immunopathology for the
host. Further investigation into specific immune cell activities and
cytokine profiles during TGF-b modulation is required to fully
elucidate the mechanisms of TGF-b regulation of influenza virus
replication.
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Ethics statement
All procedures involving animals were approved by the
Southeast Poultry Research Laboratory (USDA-ARS), University
of Wisconsin-Madison School of Medicine and Public Health, and
the St. Jude Children’s Research Hospital IACUCs and were in
compliance with the Guide for the Care and Use of Laboratory
Animals. These guidelines were established by the Institute of
Laboratory Animal Resources and approved by the Governing
Board of the U.S. National Research Council.
Laboratory facility
All experiments in which H5N1 viruses were used were
conducted in a Biosafety level 3 enhanced containment laboratory
[58]. Investigators were required to wear appropriate respirator
equipment (RACAL, Health and Safety Inc., Frederick, MD).
Mice were housed in HEPA-filtered, negative pressure, vented
isolation containers (M.I.C.E. H, Animal Care Systems, Littleton,
CO).
Cell and virus propagation
A/Turkey/Wisconsin/68 (Tk/WI, H5N9), A/Gray Teal/Austra-
lia/2/79 (N4, H4N4), A/Swine/Nebraska/2/92 (Sw/NB, H1N1),
A/Turkey/England/69 (Tk/Eng, H3N2), A/Turkey/Oregon/71
(Tk/Oreg, H7N3), A/Turkey/Ontario/6528/67 (Tk/Ont, H5N9),
A/Mallard/Wisconsin/8/76 (Mal/WI, H1N1), A/Teal/Hong
Kong/W312/97(Teal/HK, H6N1), and the 2009 H1N1 A/
California/04/09 (CA/09) and A/Wisconsin/054/09 viruses were
propagated in the allantoiccavity of 10-day-old specificpathogen-free
embryonated chicken eggs (Sunnyside Farms, Beaver Dam, WI) at
37uC. Allantoic fluid was harvested, clarified by centrifugation and
stored at 270uC. A/Puerto Rico/8 (PR8, H1N1), A/WSN/33
(WSN, H1N1), A/New Caledonia/20/99 (New Cal, H1N1), A/
Hawaii/10/2002 (Hawaii, H1N2), A/Wyoming/3/2003 (Wyom,
H3N2), A/Korea/770/2002 (Korea, H3N2), A/Aichi/2/68 (Aichi,
H3N2), and the H5N1 viruses A/Hong Kong/156/97 (HK/156),
A/Hong Kong/486/1997 (HK/486), A/Hong Kong/483/1997
(HK/483), A/Vietnam/1203/2004 (VN/1203), and A/Vietnam/
1194/2004 (VN/1194) were propagated in Madin-Darby canine
kidney (MDCK) cells as described previously [59]. Culture
supernatants were harvested, clarified by centrifugation, and stored
at 270uC. All viral titers were determined by 50% tissue culture
infectivedose (TCID50) analysis in MDCK cells and evaluated by the
method of Reed and Muench [60]. MDCK cells were cultured in
Eagle’s minimal essential medium (MEM) supplemented with 2 mM
glutamine (Mediatech, Manassas, VA), and 10% fetal bovine serum
(FBS, Gemini Bio-Products, West Sacramento, CA). Mink lung
epithelial cells stably transfected with the TGF-b-sensitive plasmin-
ogen activator inhibitor reporter construct (Mv1Lu-PAI cells,
generous gift of Dr. Daniel Rifkin, New York University) were
propagated in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 2 mM glutamine, 7% FBS, and 400 mg/ml
Geneticin (G418, Calbiochem, La Jolla, CA).
Purification of influenza virus and NA
Gray Teal influenza virus was purified by sucrose gradient
ultracentrifugation [61]. Purified Gray Teal NA was obtained
through the NIH Biodefense and Emerging Infections Research
Resources Repository, NIAID, NIH: N4 Neuraminidase (NA)
Protein from Influenza Virus, A/grey teal/Australia/2/79
(H4N4), Recombinant from baculovirus, NR-656 (BEI Resources,
Manassas, VA). Briefly, it was expressed in Sf9 cells using a
baculovirus expression vector system and purified using conven-
tional chromatographic techniques.
NA activity assay
NA enzymatic activity was determined by the MUNANA (2-(4-
methylumbelliferyl)-a-D-N-acetylneuraminic acid) assay as de-
scribed previously [62]. NA inhibition was assayed with purified
NA, and virus was standardized to equivalent NA enzyme activity
and incubated for 1 h at 37uC with oseltamivir carboxylate (0–
1000 nM, generous gift of Hoffman La-Roche, Inc., Nutley, NJ).
TGF-b assays
TGF-b activity was assessed by the plasminogen activator
inhibitor-luciferase (PAI/L) bioassay or by a TGF-b-specific
ELISA following manufacturer’s instructions (R&D Systems,
Minneapolis, MN). The ELISA is a quantitative sandwich
immunoassay where a monoclonal antibody specific for the active
region of TGF-b1 is coated onto a microplate and any bound
TGF-b1 is detected with an enzyme-linked polyclonal antibody
specific for TGF-b1. It will not detect the latent form of TGF-b1.
The PAI/L bioassay was performed as previously described [63],
with several modifications. Briefly, 2610
4 Mv1Lu-PAI cells per
well of 96-well plates were incubated overnight, washed with PBS,
and incubated with 100 ml/well test sample for 5 h at 37uC, 5%
CO2. After washing, cells were lysed and luciferase activity
measured by using a luciferase assay substrate (Promega, Madison,
WI) on a Turner Biosystems 20/20
n luminometer (Turner
Biosystems Instruments, Sunnyvale, CA). Test samples included
10 ng/ml recombinant LTGF-b1 (rLTGF-b1, R&D Systems)
incubated with different concentrations of low-protease-content
Clostridium perfringens-purified NA (Roche Applied Sciences,
Indianapolis, IN), purified NA, or influenza virus in serum-free
DMEM containing 0.1% BSA for 1 h at 37uC. To generate TGF-
b1 standard curves, 2-fold dilutions of active TGF-b1 (0–1000 pg/
ml, R&D Systems) in DMEM containing 0.1% BSA were added to
Mv1Lu-PAI cells. To determine the role of NA activity or
proteases, rLTGF-b1 was pre-incubated for 1 h at 37uC with
different NA activities of bNA, purified influenza virus, or viral NA
(as noted in figures and figure legends) in the presence of
oseltamivir carboxylate (10 nM) or 16 EDTA-free PI cocktail
(Pierce, Rockford, IL).
Protease assays
To examine the role of individual proteases, 10
6 TCID50 units/
ml of purified Tk/WI influenza virus was pre-incubated for 1 h at
37uC with bestatin (20–1000 nM; Sigma), leupeptin (10–100 mM;
Sigma), or GM 1489 (1–500 nM; Calbiochem), followed by
incubation with 10 ng/ml rLTGF-b1 for 1 h at 37uC. LTGF-b1
activation was determined by the PAI/L assay. All protease
inhibitors were used within their effective inhibitory concentra-
tions, as determined by the manufacturer. To test for the presence
of proteases in experimental reagents, including purified virus,
proteins, and inhibitors, a thiocarbamoyl-casein derivative-based
assay was used as per manufacturer’s instructions (Calbiochem) in
the presence or absence of 16protease inhibitor cocktail (Pierce).
LTGF-b Western blot and sialic acid content
rLTGF-b (0.4 mg) or rLAP (0.5 mg, R&D Systems) was
incubated with PBS, HCl (final pH of 2), purified Gray Teal
virus (2 mg), purified Gray Teal NA (0.5 mg), or bNA either alone
or pre-incubated with NAi (1 mM) or 16 PI for 1 h at 37uCa s
described previously. Samples were then separated on a 5%–20%
SDS-PAGE gel under reducing conditions. After transferring to
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buffered saline plus 1% Tween 20 (TTBS) for 1 h at room
temperature and probed for LAP with mouse-anti-LAP (1:500,
R&D Systems) in TTBS for 1 h at room temperature. Blots were
washed and incubated with goat anti-mouse-HRP (1:5000,
Jackson Laboratories, Bar Harbor, ME). To examine the sialic
acids present on LAP, TGF-b samples were prepared as described
above and blots were probed with DIG-labeled MAA (1:200),
which recognizes a2,3-linked sialic acids, or SNA (1:1000), which
recognizes a2,6-linked sialic acids, for 1 h at room temperature
(DIG glycan differentiation kit, Roche Applied Science). Lectins
were visualized by staining with anti-DIG-AP. After detection,
blots were analyzed by Western blotting for LAP, as described
above.
Reverse genetics
H5N1 reverse genetic viruses were generated by the RNA
polymerase I reverse genetics system [64]. The PR8 and CA/09
virus expressing HK/483 NA was constructed by using the eight-
plasmid system as previously described [65]. P1 viral stocks were
generated, the NA genes sequenced to ensure that no spurious
mutations arose during viral propagation, stiters determined by
TCID50 analysis in MDCK cells, and NA activity quantitated by
the MUNANA assay as described above. To determine TGF-b
levels with the reassortant viruses, BALB/c mice were lightly
anesthetized and inoculated with 10
4 TCID50 units of the different
reassortant viruses or PBS alone, as described below.
TGF-b modulation in vivo
To deplete TGF-b activity during HK/486 and CA/09 virus
infection, 4- to 6-week-old BALB/c mice (Charles River Labora-
tories, Wilmington, MA) were intraperitoneally (i.p.) inoculated
with PBS, anti-TGF-b neutralizing antibody 1D11, or isotype-
matched mouse IgG (0.5 mg per mouse, Sigma) in PBS 6 to 48 h
pre-infection and then every 48 hpi. Mice were then intranasally
(i.n.) inoculated with 25 ml PBS or 10
5 TCID50 virus. 1D11 was
either purchased (R&D Systems) or purified from the 1D11
hybridoma (ATCC# 1D11.16.8). 1D11 produces IgG1 antibodies
that neutralize all 3 mammalian TGF-b isoforms (b1, b2, b3) [66].
IgG was purified from cell culture supernatants by T-Gel (Pierce),
potential endotoxin contaminations removed by Detoxi Gel
Endotoxin Removing Gel (Pierce), and purified IgG concentrated
and buffer exchanged with Amicon Ultra-15 concentrators
(Millipore, Bedford, MA). The endotoxin levels were less than 0.2
EU/mg as measured by the Biowhittaker QCL-1000 assay
(Biowhittaker, Walkersville, MD).
Exogenous active TGF-b1 was administered to mice by
infection with a replication-defective adenovirus expressing active
TGF-b1 (AdTGFb
223/225) or the control vector (AdDL70) as
described previously [67,68]. Briefly, full-length porcine TGFbb1
cDNA (differing from murine TGF-b1 by 1 amino acid) was
mutated at serine 223 and 225 (TGF-b
223/225) to render the
protein constitutively active and expressed in a recombinant,
replication-deficient type-5 adenovirus. The replication-deficient
virus (AdTGFb
223/225) was purified by cesium chloride (CsCl)
gradient centrifugation and concentrated by using a Sephadex PB-
10 chromatography column. Mice were i.n. inoculated with 10
8
PFUs of active AdTGFb
223/225 or AdDL70 either 48 h pre- or
24 h post-infection with 10
4 TCID50 units of HK/483 virus. Mice
were monitored daily and weighed every 48 h post-infection. At
different time points post-infection, 2 mice from the control group
and 3 mice from the experimental group were euthanized and
lungs collected. Tissues were homogenized in cold PBS, and
clarified tissue homogenates were tested for TGF-b levels, using a
mouse-specific ELISA (R&D Systems) or viral titers by TCID50
analysis on MDCK cells.
Statistical analyses
Statistical significance of data was determined by using analysis
of variance (ANOVA) or Student’s t- test on GraphPad Prism (San
Diego, CA). All assays were run in triplicate and are representative
of at least 2 separate experiments. Error bars represent standard
deviation, and statistical significance was defined as a p value of
less than 0.05.
Supporting Information
Figure S1 Gray Teal NA does not cleave a2-6 linked sialic acids.
rLTGF-b (0.4 mg) was incubated with PBS, bNA, or purified GT
NA (0.5 mg) for 1 h at 37uC. Proteins were separated by SDS-
PAGE under reducing conditions, transferred to nitrocellulose,
and probed with digoxigenin-labeled SNA lectin. bNA and GT
NA alone were run as controls.
Found at: doi:10.1371/journal.ppat.1001136.s001 (0.54 MB EPS)
Figure S2 Endogenous protease activity in influenza virus
stocks. FTC-casein derivative was incubated with PBS, trypsin
(positive control), bNA (30,000 RFU), or 90,000 RFU of different
influenza virus strains or GT NA in the presence (red bar) or
absence (black bar) of 16 PI cocktail for 24 h at 37uC.
Fluorescence measured at excitation 490 nm and emission
525 nm. Results are expressed as fold increase over the negative
control. Asterisk (*) indicates significant increase as compared with
the negative control.
Found at: doi:10.1371/journal.ppat.1001136.s002 (0.44 MB EPS)
Figure S3 Pretreatment with exogenous TGF-b does not
prolong survival in HK/483-infected mice. BALB/c mice (4–6
weeks) were inoculated i.n. with PBS (control) or 10
8 PFU/mouse
of a TGF-b-expressing adenovirus (AdTGFb
223/225)o ra n
adenovirus vector control (AdDL70) (n=12) 48 h before inocula-
tion with 10
4 TCID50 units of HK/483 virus (n=12). Mice
inoculated with AdDL70 or AdTGFb
223/225 alone served as
controls (n=10). Weights (A) and survival (B) were monitored for
10 dpi. Asterisk (*) indicates significant difference in weight loss as
compared to HK/483 infected mice.
Found at: doi:10.1371/journal.ppat.1001136.s003 (0.57 MB EPS)
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